Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Original) A DNA according to any one of the following (a) to (d):

(a) a DNA encoding a protein comprising the amino acid sequence of SEQ ID NO: 2 or 4,

(b) a DNA comprising the coding region of the nucleotide sequence of SEQ ID NO: 1 or 3,

(c) a DNA encoding a protein comprising an amino acid sequence in which one or more amino acids in the amino acid sequence of SEQ ID NO: 2 or 4 have been replaced, deleted, inserted, and/or added,

(d) a DNA capable of hybridizing with a DNA comprising the nucleotide sequence of SEQ ID NO: 1 or 3 under stringent conditions.

2. (Original) The DNA of claim 1 encoding a protein capable of binding to a protein selected from the group consisting of SHP-1 protein, SHP-2 protein, SHIP protein, DAP10 protein, DAP12 protein, and FcRγ protein.

3. (Original) A protein encoded by the DNA of claim 1.

4. (Original) A vector into which the DNA of claim 1 has been inserted.

5. (Currently amended) A host cell carrying the DNA of claim 1~~, or the~~ or a vector ~~of claim 4~~ into which the DNA of claim 1 has been inserted.

6. (Currently amended) A method for producing ~~the~~ a protein ~~of claim 3~~, which comprises the steps of culturing the host cell of claim 5, and recovering [[an]] the expressed protein from said host cell or the culture supernatant thereof.

7. (Original) An antibody that binds to the protein of claim 3.

8. (Original) A polynucleotide comprising at least 15 nucleotides that is complementary to a DNA comprising the nucleotide sequence of SEQ ID NO: 1 or 3, or the complementary strand thereof.

9. (Original) A method of screening for a compound that binds to the protein of claim 3, which comprises the following steps of:

(a) contacting said protein with a test sample,

(b) detecting the binding activity between said protein and said test sample, and

(c) selecting a compound capable of binding to said protein.

10. (Original) A method of screening for a compound capable of inhibiting the binding between the protein of claim 3 and a protein selected from the group consisting of SHP-1 protein, SHP-2 protein, SHIP protein, DAP10 protein, DAP12 protein, and FcRγ protein, which comprises the following steps of:

(a) contacting the protein of claim 3 with a protein selected from said group in the presence of a test sample,

(b) detecting the binding activity between said proteins, and

(c) selecting a compound capable of reducing the binding activity between said proteins compared to that detected in the absence of said test sample.

11. (Currently amended) A method for producing an anti-allergy drug, which comprises the step of mixing the antibody of claim 7~~, or a compound obtained using the method of claim 9 or 10,~~ with a pharmacologically acceptable carrier or vehicle.

12. (New) A method for producing an anti-allergy drug, which comprises the step of mixing a compound obtained using the method of claim 9 with a pharmacologically acceptable carrier or vehicle.

13. (New) A method for producing an anti-allergy drug, which comprises the step of mixing a compound obtained using the method of claim 10 with a pharmacologically acceptable carrier or vehicle.